1Langer C J, Natale RB. The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors [J].Semin Oncol, 2005,32(6 Suppl 10) : $23-29. 被引量：1
2Laskin JJ, Sandler AB. First-line treatment for advanced nonsmall-cell lung cancer [J]. Oncology (Huntington), 2005,19(13) : 1671-1676. 被引量：1
3Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced nonsmall-cell lung cancer: a phase Ⅲ trial-INTACT 2[J]. J Clin Oncol, 2004,22(5) :785-794. 被引量：1
4Fuster LM, Sandier AB. Select clinical trials of erlotinib (0SI774) in non-small-cell lung cancer with emphasis on phase Ⅲ outcomes [J]. Clin Lung Cancer, 2004,6 Suppl 1 :S24-29. 被引量：1
5Wakelee H, Belani CP. Optimizing first-line treatment options for patients with advanced NSCLC [J]. Oncologist, 2005,10 Suppl 3:1-10. 被引量：1
6Kelly K, Crowley J, Paul A, et al. Randomized phase Ⅲ trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer:a southwest oncology group trial [J]. J Clin Oncol,2001,19(13) :3210-3218. 被引量：1
4M. Reck,J. von Pawel,P. Zatloukal,R. Ramlau,V. Gorbounova,V. Hirsh,N. Leighl,J. Mezger,V. Archer,N. Moore,C. Manegold.Overall survival with cisplatingemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Annals of Oncology . 2010 被引量：2
5Craig Reynolds,David Barrera,Robert Jotte,Alexander I. Spira,Charles Weissman,Kristi A. Boehm,Sharon Pritchard,Lina Asmar.Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell Lung Cancer[J]. Journal of Thoracic Oncology . 2009 (12) 被引量：1
6Johnson DH,Fehrenbacher L,Novotny WF,et al.Randomized phaseⅡtrial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. Journal of Clinical Oncology . 2004 被引量：1
7Manegold C,von Pawel J,Zatloukal P,et al.Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-na?ve patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704. Journal of Clinical Oncology . 2007 被引量：1
8Sandler Alan,Gray Robert,Perry Michael C,Brahmer Julie,Schiller Joan H,Dowlati Afshin,Lilenbaum Rogerio,Johnson David H.Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. The New England Quarterly . 2006 被引量：1
9Reck Martin,von Pawel Joachim,Zatloukal Petr,Ramlau Rodryg,Gorbounova Vera,Hirsh Vera,Leighl Natasha,Mezger J?rg,Archer Venice,Moore Nicola,Manegold Christian.Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. Journal of clinical oncology : official journal of the American Society of Clinical Oncology . 2009 被引量：1
10Sandler A,Gray R,Perry MC,et al.Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. New England Journal of Medicine, The . 2006 被引量：1
